[go: up one dir, main page]

MX2007003910A - T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. - Google Patents

T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Info

Publication number
MX2007003910A
MX2007003910A MX2007003910A MX2007003910A MX2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A
Authority
MX
Mexico
Prior art keywords
tcr
cell receptors
terminus
amino acid
acid sequence
Prior art date
Application number
MX2007003910A
Other languages
Spanish (es)
Inventor
Bent Karsten Jakobsen
Torben Bent Andersen
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0421836.8A external-priority patent/GB0421836D0/en
Priority claimed from GB0427584A external-priority patent/GB0427584D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of MX2007003910A publication Critical patent/MX2007003910A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention provides a dimeric TCR (dTCR) or single-chain TCR (scTCR) associated with selected therapeutic agents, wherein said TCR comprises a first segment constituted by an amino acid sequence corresponding to a TCR chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR chain constant domain extracellular sequence, a second segment constituted by an amino acid sequence corresponding to a TCR a chain variable domain fused to the N terminus of an amino acid sequence corresponding to TCR a chain constant domain extracellular sequence, a disulfide bond between the first and second chains, said disulfide bond being one which has no equivalent in native a T cell receptors, and in the case of said scTCRs further comprising a linker sequence linking the C terminus of the first segment to the N terminus of the second segment, or vice versa, the length of the linker sequence and the position of the disulfide bond being suc h that the variable domain sequences of the first and second segments are mutually orientated substantially as in native a T cell receptors.
MX2007003910A 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. MX2007003910A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0421836.8A GB0421836D0 (en) 2004-10-01 2004-10-01 T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
US62106304P 2004-10-25 2004-10-25
GB0427584A GB0427584D0 (en) 2004-12-16 2004-12-16 T cell receptors containing a novel disulfide interchain bond linked to immunomodulatory agents
PCT/GB2005/003752 WO2006037960A2 (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents

Publications (1)

Publication Number Publication Date
MX2007003910A true MX2007003910A (en) 2007-06-07

Family

ID=36000822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003910A MX2007003910A (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Country Status (6)

Country Link
EP (1) EP1809669A2 (en)
JP (1) JP2008514685A (en)
AU (1) AU2005291039A1 (en)
CA (1) CA2582963A1 (en)
MX (1) MX2007003910A (en)
WO (1) WO2006037960A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
ES2975748T3 (en) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentation of bonding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102161998B (en) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof
CA2838013C (en) * 2011-06-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
EP2755993B1 (en) 2011-09-16 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
CA2850291A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN103130894B (en) * 2011-11-30 2017-04-12 中国医学科学院基础医学研究所 Recombinant single-chain antibody G5-4ScFv of anti-human gamma delta T cell receptor (TCR) monoclonal antibody and encoding gene and application thereof
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US10654906B2 (en) 2013-06-26 2020-05-19 Guangdong Xiangxue Life Sciences, Ltd. High-stability T-cell receptor and preparation method and application thereof
JP6415716B2 (en) * 2014-11-07 2018-10-31 グアンドン シャンスエ ライフ サイエンス， リミテッド． Soluble heterodimeric T cell receptor and process and use thereof
CN106279404A (en) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 A kind of solvable and stable heterogeneous dimerization TCR
WO2017193107A2 (en) 2016-05-06 2017-11-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
HRP20250113T1 (en) 2016-06-02 2025-03-28 Immunocore Limited DOSAGE REGIME FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
KR20250072712A (en) * 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 Synthetic immune receptors and methods of use thereof
KR20190118172A (en) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. Multispecific Binding Proteins for Activation of Natural Killer Cells and Their Therapeutic Uses in Cancer Treatment
JP7685821B2 (en) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Proteins that bind to Her2, NKG2D and CD16
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN111527209B (en) 2017-11-01 2024-11-12 爱迪塔斯医药股份有限公司 Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
KR20200079312A (en) 2017-11-06 2020-07-02 에디타스 메디신, 인코포레이티드 CRISPR-CAS9 editing method, composition and components of CBLB in T cells for immunotherapy
CN112040971A (en) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 Combination cancer therapy involving multispecific binding proteins that activate natural killer cells
DK3749346T3 (en) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc ANTIBODY VARIABLE DOMAIN COMBINATIONS TARGETING THE NKG2D RECEPTOR
TW201942134A (en) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
BR112020020245A2 (en) 2018-04-05 2021-04-06 Editas Medicine, Inc. METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
EP3775237A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
MX2020010460A (en) 2018-04-05 2021-01-29 Juno Therapeutics Inc T-CELL RECEPTORS, AND ENGINEERED CELLS EXPRESSING THEM.
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
KR20250112921A (en) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CA3172447A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021243864A1 (en) 2020-03-27 2022-11-03 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
CN116234558A (en) 2020-06-26 2023-06-06 朱诺治疗学有限公司 Engineered T cells, related polynucleotides and methods for conditionally expressing recombinant receptors
CA3182607A1 (en) 2020-06-30 2022-01-06 Erik Hans MANTING Use of leukemia-derived cells in ovarian cancer vaccines
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
CN117222663A (en) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 Methods of treating cancer using multispecific binding proteins that bind NKG2D, CD16, and tumor-associated antigens
KR20240004937A (en) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 BMA031 antigen-binding polypeptide
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN116496408A (en) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 Interleukin 21 and receptor complexes thereof
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531208A (en) * 2001-08-31 2005-08-26 Avidex Ltd Multivalent soluble T cell receptor (TCR) complexes
CA2501870C (en) * 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
EP2048159B1 (en) * 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
WO2004050705A2 (en) * 2002-12-03 2004-06-17 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
EP1809669A2 (en) 2007-07-25
JP2008514685A (en) 2008-05-08
WO2006037960A2 (en) 2006-04-13
AU2005291039A1 (en) 2006-04-13
CA2582963A1 (en) 2006-04-13
WO2006037960A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
MX2007003910A (en) T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.
NO20052198L (en) Single-chain, recombinant T-cell receptors
JP2006502741A5 (en)
MX2012003939A (en) Drug fusions and conjugates with extended half life.
HRP20220865T1 (en) T cell receptors
PE20120514A1 (en) FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS OR DRUGS INCRETINE WITH DAB ANTI-SERIAL ALBUMIN ANTIBODIES
UY31123A1 (en) NATURAL FUSION PROTEINS
PE20140260A1 (en) ANTIDIABETIC COMPOUNDS
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
MX2015006868A (en) Methods for making conjugates from disulfide-containing proteins.
AR062030A1 (en) EXENDINE FUSION PROTEINS
HRP20170086T1 (en) Bifunctional polypeptides
PE20171325A1 (en) POLYPEPTIDES OF THE VARIANT ACTIVIN RECEPTOR AND USE OF THEM
CY1118243T1 (en) NEW TRANSPORT CONTAINERS AND LOAD TRANSPORT CONTAINER PARTS
WO2014052451A3 (en) Insulin analog dimers
PL1761553T3 (en) Tumor-associated peptides that bind to mhc-molecules
PE20141045A1 (en) BCMA BINDING PROTEINS (CD269 / TNFRSF17)
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
CY1121580T1 (en) NOVEL β-RAY AND RPS21 PROMOTERS AND THEIR USES
PE20161153A1 (en) LONG-ACTING INSULIN AND USE OF THE SAME
HRP20110240T1 (en) Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
NO20071592L (en) GLP-1 and exendin-related invention
ATE388964T1 (en) MODIFIED SOLUBLE T-CELL RECEPTOR
ATE527353T1 (en) PDGF-BINDING POLYPEPTIDE FROM PROTEIN A
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ALSTOM RENEWABLE TECHNOLOGIES

FA Abandonment or withdrawal